| HKI-272 |
| (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide |
| (CAS 698387-09-6) |
 |
| Description： |
Neratinib (HKI-272) is a tyrosine kinase inhibitor[1][2] under investigation for the treatment breast cancer and other solid tumours.
It is in development for the treatment of early- and late-stage HER2-positive breast cancer.
Like lapatinib and afatinib, it is a dual inhibitor of the human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases.
|
| Product No. |
KT00428 |
| Product Name |
HKI-272 |
| Synonyms |
|
| Formal Name |
(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide |
| CAS Number |
698387-09-6 |
| Molecular Formula |
C30H29ClN6O3 |
| Formula Weight |
557.04 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
AEE788
Afatinib
AG 18
AG-1478
AG-490
ARRY-380
AST-1306
AST-1306 TsOH
AV-412
AZD-9291
|
|
